Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured. The underlying cause for resistance to treatment in 20 ± 30% of metastatic lesions remains to be identi®ed. Unlike other solid tumors, no mutations in the TP53 gene have been identi®ed to date in random panels of GCT specimens, which could account for the exquisite sensitivity of these tumors to genotoxic insult. However, in a panel of resistant GCTs that did either not respond to cisplatin-based chemotherapy or subsequently relapsed and resulted in the death of the patient, we have now identi®ed a subset of tumors to contain TP53 mutations within exons 6 ± 9. A cell line derived from one of these tumors (228A) displayed the same TP53 mutation as the tumor specimen, expressed only mutant TP53 mRNA, and exhibited a relative resistance to cisplatin in vitro in comparison to a cell line (218A) derived from a responsive tumor with wild-type TP53. The resistant cell line displayed a much reduced apoptotic cell death and did not exhibit an induction of transcription of the p53-responsive genes WAF1 and MDM2 following cisplatin treatment, compared to that observed in the sensitive cell line. The levels of bax, an agonist of apoptosis, were found to be reduced in the resistant cell line. The simplest explanation for the resistance of this subset of GCTs that are resistant to cisplatin-based chemotherapy, is the inability of the cells to mount an apoptotic response following exposure due to a functionally inactivating mutation in the TP53 gene.
Introduction
The tumor suppressor gene TP53 is commonly mutated in human cancer, with approximately 50% of tumors estimated to contain a mutation (Harris, 1996) . The resulting loss of p53 function is thought not only to contribute to tumor formation, but also progression and resistance to treatment (Harris and Hollstein, 1993) . Mutations tend to localize to hot spots within the sequence-speci®c DNA binding domain of p53 and hence are thought to interfere with at least one of the functions of p53 as a transcription factor (Harris, 1996; Ko and Prives, 1996) . Exposure of cells to genotoxic agents such as those used in the treatment of cancer, results in an induction of the levels of p53 that can mediate either a delay in cell cycle progression or the induction of cell death via an apoptotic pathway (Ko and Prives, 1996; Levine, 1997) . While the precise mechanisms whereby p53 elicits these responses is unclear, several p53-responsive genes have been identi®ed that may be involved: WAF1 encoding the cell cycle inhibitor p21 (El-Diery et al., 1993) , MDM2 encoding a protein that complexes with p53 providing a regulatory loop (Barak et al., 1993) , and BAX encoding a BCL2-related protein acting as an agonist of apoptosis (Miyashita and Reed, 1995) . The determinant of cellular response to genotoxic insult, delay or apoptosis, appears to be cell-type speci®c and may in part be in¯uenced by inherent ratios of members of the BCL2 family (BCL2, BAX, BCLX) (White, 1996; Yang and Korsmeyer, 1996) , by p21 (Canman et al., 1995; Polyak et al., 1996) , and by other as yet unidenti®ed trans-acting factors (Polyak et al., 1996) . It is clearly apparent that functional inactivation of p53 by mutation could explain the lack of response by tumor to chemotherapeutic treatment.
Unlike most other solid tumors, male germ cell tumors which arise in the spermatogenic lineage, exhibit an exquisite sensitivity to a variety of chemotherapeutic agents . Germ cell tumors predominantly arise in the testis, with less than 10% presenting at extragonadal sites. Another unique feature of these tumors is the array of histopathologies observed in vivo that resemble dierent stages of embryonic differentiation (Ulbright, 1993) . At the present time, more than 90% of all newly diagnosed patients and 70 ± 80% of patients with metastatic disease are cured . Treatment usually involves surgical resection of the tumor followed by cisplatin-based chemotherapy. In contrast to other tumor types, no TP53 mutations have been detected in GCTs studied to date (Heimdal et al., 1993; Peng et al., 1993; reviewed in Chaganti et al., 1996) , which could explain the extreme sensitivity of these tumors to genotoxic agents observed in vivo . While it has been reported that GCTs express higher than normal levels of wild-type p53 (Bartkova et al., 1991; Riou et al., 1995) , recent studies in a murine teratocarcinoma cell line have indicated that this p53 is in a functionally inactive state (Lutzker and Levine, 1996) . Exposure of the cells to the indirect DNA-damaging agent etoposide resulted in activation of p53 function, as assayed by the transcriptional activity. The high levels of p53 in GCTs may re¯ect the cellular origin of these tumors (Chaganti et al., 1996) and suggest a lack of selective advantage for TP53 mutation in these cells.
Despite the success of treatment of most male GCTs with the regimen just described, 20 ± 30% of metastatic lesions exhibit resistance to treatment with an unknown underlying cause. We have examined a panel of male GCTs that displayed a clinical resistance to cisplatin-based chemotherapy and have identi®ed TP53 mutations in a subset of these tumors. A cell line derived from one such specimen containing a TP53 mutation, exhibited in vitro a relative cellular resistance to cisplatin treatment, and lack of induction of transcription of p53-responsive genes following treatment. Hence, TP53 mutations do occur in male GCTs albeit at a very low frequency and may account for the resistance of these tumors to cisplatin-based treatment.
Results

TP53 mutations in resistant GCTs
From a bank of GCT specimens, 28 tumor specimens derived from 23 patients were selected for single strand conformation polymorphism (SSCP) analysis of TP53. Selection was based upon the responsiveness of the tumor to cisplatin-based chemotherapy: it did either not respond to chemotherapy, or initially responded and subsequently relapsed, resulting in death of the patient. Of these 28 specimens, all histologies were represented: ®ve seminomas, four embryonal carcinomas, eight teratomas, three yolk sac tumors, three choriocarcinomas, three mixed nonseminomatous tumors, and two teratomas with malignant transformation (one of which was a rhabdomyosarcoma). Seven specimens were from primary tumors while the remaining 21 were from relapsed tumors. SSCP analysis was performed on extracted DNA using genomic primers speci®c for exons 5 ± 9. Analysis was restricted to these exons, as in other tumor types mutations are found predominantly within these exons (Harris, 1996) . Variants were identi®ed and puri®ed PCR products were sequenced to con®rm the presence of a mutation. Five tumor specimens from four relapsed patients exhibited mutations in TP53 with the identity of the respective mutations listed in Table  1 . Three patients died of disease, while the fourth from which T-199A was resected, was lost to follow-up and was reported to have died of unrelated causes. All the mutations were identi®ed in GCTs with a teratomatous histology, including one case with malignant transformation into rhabdomyosarcoma (T-203A,B). Both lesions (teratoma and rhabdomyosarcoma) from this patient exhibited the identical deletion of three nucleotides at codon 191. In the remaining three cases, missense mutations were identi®ed that resulted in amino acid alterations. The mutations occurring within tumors T-349B and T-228A were within mutational hot spots identi®ed in other tumor types (Harris, 1996) , and all lie within the sequence-speci®c DNA binding region of p53 (codons 100 ± 293), with the exception of tumor T-199A (codon 299). These results indicate that at least a subset of tumors resistant to chemotherapy contain TP53 mutations that may contribute to their lack of response to treatment.
Response of GCT cell lines to cisplatin
A cell line was derived from tumor T-228A that upon SSCP analysis and subsequent sequencing was found to exhibit the same TP53 mutation as that identi®ed in the tumor specimen. Sequence analysis revealed that the cell line which has been maintained continuously in culture for at least 40 passages, is heterozygous for the mutation (data not shown). Patient 228A responded to chemotherapy, but within one year of treatment relapsed and ultimately died of disease. An additional cell line (218A) was derived from a teratoma resected from a patient that responded to chemotherapy and has remained without evidence of recurring disease. SSCP analysis revealed no evidence of TP53 mutations in DNA extracted from this cell line. In order to test if the responsiveness of the patient's tumor to cisplatin in vivo could be re¯ected in vitro and whether this responsiveness is associated with the mutation in TP53, the two cell lines, 218A and 228A, were exposed to cisplatin for 2 h at doses of 0, 4, and 8 mg/ml. Cells were collected and viable cells assayed by trypan blue exclusion every day up to four days post-treatment (Figure 1 ). It is apparent that the same dose of cisplatin in cell line 218A caused an extensive decrease in viable cell count, while in cell line 228A, much less of a decrease was observed. In order to determine if the observed decrease in viable cell counts was due to cell death arising through an apoptotic mechanism, cells were ®xed at 5 and 24 h posttreatment and stained with Hoescht 33528 to assay for chromatin condensation, an event associated with apoptotic cell death. The number of cells exhibiting apoptotic bodies was markedly higher in cell line 218A compared to cell line 228A, at both time points and doses (Table 2 ). These results indicated that cisplatin induced cell death through an apoptotic mechanism in cell line 218A to a greater extent than that observed in cell line 228A. The simplest explanation for the failure of cell line 228A to respond to cisplatin is the inability of the cells to mount an apoptotic response due to lack of functional p53. Both cell lines appeared to express normal-sized TP53 mRNA and p53 (Figure 2) . Analysis of the TP53 mRNA in cell line 228A by RT ± PCR followed by sequencing analysis, indicated that only mutant mRNA was being expressed (Figure  3) . Hence the other TP53 allele in cell line 228A is not being transcribed, and would appear to be inactivated by a mechanism other than loss of the gene, as loss of heterozygosity was not detected at this locus using an intragenic microsatellite STS marker (data not shown). Small deletions and/or mutations outside of exons 5 ± 9 in this allele have not as yet been ruled out as other possible causes. Whether the mutant p53 in cell line 228A was lacking in function, providing an explanation for the lack of apoptotic response to cisplatin, was tested by exposure of the two cell lines to cisplatin for 2 h, and the expression of known p53-responsive genes assayed at both the mRNA and protein levels at 5 and 24 h post-treatment (Figure 2 ). In the sensitive cell line 218A, the levels of p53 were induced markedly by cisplatin, which could only partly be accounted for by an increase in transcriptional rate, as noted in other cells after genotoxic insult (Ko and Prives, 1996) . No such increase was observed in 228A (Figure 2 ), possibly re¯ective of an inability to activate the mutant p53 and subsequently it's inability to function as a transcription factor. Levels of bax, an agonist of apoptotic cell death, were noted to be higher in untreated 218A cells than in 228A cells, and after treatment, a small induction of bax was only observed in the sensitive cell line (218A). Transcript levels of both the WAF1 and MDM2 genes were found to be elevated in 218A after cisplatin exposure, with no comparable induction observed in 228A (Figure 2) . These results indicated that the mutant p53 present in 228A was unable to function to activate the transcription of genes known to be induced by p53 after genotoxic insult, that may act as mediators of p53 function.
Discussion
Previous studies have indicated a lack of TP53 mutations in GCT specimens which has been suggested to account for the exquisite sensitivity of these tumors to cisplatin-based chemotherapy (Heimdal et al., 1993; Peng et al., 1993; Chaganti et al., Figure 3 Sequence analysis of RT ± PCR product generated from cell line 228A. Total RNA from the resistant cell line 228A was submitted to RT ± PCR, and the product was sequenced using an antisense primer. The sequence analysis indicates that only mutant TP53 mRNA (GAG at codon 279) is being expressed. The wild-type TP53 sequence for this codon is GGG. The asterisk denotes the mutation observed in the antisense orientation TP53 mutation in resistant male germ cell tumors J Houldsworth et al 1996) . These studies comprised panels of unselected GCTs, and it was only when a panel of GCTs observed clinically to be resistant to such treatment did we identify TP53 mutations in a subset of tumors. Interestingly these tumors were all of a teratomatous histology, with one tumor displaying malignant transformation into a rhabdomyosarcoma that exhibited the same TP53 mutation. Hence, TP53 mutations do occur in male GCTs albeit at a very low frequency. GCTs have been reported to express high levels of wild-type p53 (Bartkova et al., 1991; Riou et al., 1995) which is thought to re¯ect the cell of origin (Chaganti et al., 1996) . It has been postulated by us that male GCTs arise in pachytene spermatocytes through selection of an aberrant recombinational event that permits the re-entry of the cell into a mitotic cell cycle (Chaganti et al., 1996) . High levels of p53 have been detected at this stage of meiosis during murine spermatogenesis possibly re¯ective of the elevated strand breaks present in such cells associated with genetic recombination (Schwartz et al., 1993) . Constitutive high levels of p53 may explain the lack of selective advantage for TP53 mutation noted in these tumors. A recent study in a murine teratocarcinoma cell line (F9) has indicated that while such cells have high levels of p53, it is in a functionally inactive form (Lutzker and Levine, 1996) . Only upon treatment of the cells with either etoposide, an indirect DNA damaging agent, or cAMP, an agent that induces dierentiation of the cells, did the p53 exhibit activity in inducing the transcription of reporter genes with a p53-responsive promoter. The functional activity of the high levels of p53 in human male GCTs has not as yet been determined. We have now identi®ed a small subset of resistant GCTs with TP53 mutations that may account for their resistance to cisplatin-based chemotherapy. The role of p53 in the resistance phenotype was con®rmed by the treatment of a GCT cell line derived from one such resistant tumor. In this cell line, a much reduced degree of apoptotic cell death and a lack of induction of p53-responsive genes was observed after cisplatin treatment, compared to a sensitive GCT cell line. Male GCTs provide an excellent model system for the study of genotoxin-induced apoptotic cell death. As shown in this study and in another, male GCTs display an apoptotic response to treatment with agents that cause damage to DNA, which would appear to be at least in part p53-dependent (Chresta et al., 1996) . Despite an induction of WAF1 observed after genotoxic stress, a G1 arrest has not been observed in GCT cell lines studied to date (Chresta et al., 1996; unpublished observations) . The determinants of a cell's decision to enter apoptosis or G1 arrest would appear to involve a number of factors: ratios of the BCL2 family, particulary the BCL2 : BAX ratio (White, 1996; Yang and Korsmeyer, 1996) , p21 (Canman et al., 1995; Polyak et al., 1996) , and other trans-acting factors (Polyak et al., 1996) . In GCTs these factors favor apoptosis. In this study, bax levels were higher in the sensitive cell line (218A) than in the resistant line (228A), and neither expressed detectable levels of bcl-2 which would act as an antagonist of apoptosis (data not shown). Similar results were reported for other GCT cell lines (Chresta et al., 1996) . These studies may indicate that the BCL2:BAX ratio in GCTs favors cell death. Perhaps resistance observed in another subset of GCTs could be accounted for by an alteration in this ratio, decreasing the tendency for induced cell death. One of the other factors thought to play a role in determining the cellular response to genotoxic insult is p21. WAF1, which encodes p21, is itself a p53-responsive gene. Some studies have indicated that high levels of p21 induced by p53-independent means in some cell types, may protect cells from apoptosis (Canman et al., 1995; Polyak et al., 1996) . A relative resistance of mature teratomas (GCTs that display a highly dierentiated somatic phenotype) to chemotherapy has been reported, though without deleterious eect on patient survival . It is possible that such resistance could be due to elevated levels of p21 often observed normally in more dierentiated cells, by such a p53-independent mechanism.
While the study reported here has identi®ed a small subset of GCTs with TP53 mutations that may account for their resistance to cisplatin-based chemotherapy, the cellular mechanisms whereby resistance is achieved in the remaining tumors is unknown. Clinical studies have identi®ed choriocarcinomas (GCTs resembling an extra-embryonic pattern of dierentiation) and GCTs presenting at extragonadal sites to be particularly resistant to treatment. It is possible that molecular cytogenetic techniques such as comparative genomic hybridization may identify speci®c chromosome regional gains and losses of DNA that may be associated with resistance in these tumor types.
Materials and methods
Tumors, cell lines, and culture conditions
Tumor specimens were obtained during surgery of patients treated at the Memorial Sloan-Kettering Cancer Center. Both of the cell lines were derived from metastatic lesions (teratomas) from patients with Stage II disease who have had primary gonadal tumors and prior chemotherapy. Cell lines were derived by mechanical dispersion of the tumor specimen followed by growth in culture, and have been subsequently maintained for at least 40 passages. At early (510) and later passages (51 for 218A, and 32 for 228A), cultures were collected for G-banded cytogenetic analysis, and also tested for the presence of extra copies of 12p as previously described (Houldsworth et al., 1997) . The cell lines were maintained in DMEM supplemented with 15% fetal bovine serum, 2 mM glutamine, and 100 units/ml penicillin and streptomycin (Life Technologies Inc.). Cells were grown as monolayers on¯asks or dishes pretreated with normal human ®broblast-conditioned growth medium. Cells were plated out 24 h prior to treatment with cisplatin (Bristol-Meyers) and were either mock-treated or treated with 4 or 8 mg/ml cisplatin for 2 h. Cultures were washed three times with phosphate-buered saline (PBS), and fresh medium returned to the dishes. At appropriate time points post-treatment, cultures were collected and submitted for viability, apoptotic, and RNA and protein analyses as described below.
SSCP analysis and direct DNA sequencing DNA was extracted from tumor specimens and cell lines using standard techniques and submitted to SSCP analysis as described (Xu et al., 1994) . Exons 5 ± 9 of TP53 were tested at least twice for each sample and the puri®ed PCR TP53 mutation in resistant male germ cell tumors J Houldsworth et al products of detected SSCP variants were directly sequenced to con®rm the presence of a mutation.
RT ± PCR and sequencing analysis
Total RNA was extracted from the cell lines using an RNAgents isolation kit (Promega). First strand cDNA was synthesized using an RT-PCR kit (Stratagene) with an oligo (dT) primer. PCR was then performed using forward (5'-GTTGGCTCTGACTGTACC-3') and reverse (5'-TCG-CTTAGTGCTCCCTGG-3') primers speci®c for wild-type TP53 cDNA. The resulting 246 bp fragment was gelpuri®ed and sequenced using the reverse primer.
Viability and apoptosis assays
At indicated time points after cisplatin treatment, viable cell counts were performed using a trypan blue exclusion assay. In addition, cell pellets were ®xed in 3% paraformaldehyde, prior to staining with Hoescht 33528 (Sigma). Cells were considered to be apoptotic if two or more`apoptotic bodies', representative of chromatin condensation, per cell were observed. At least 500 cells were counted per culture.
Northern blotting and immunoblotting
Northern hybridization was performed on extracted total RNAs as described elsewhere (Houldsworth et al., 1997) .
The ®lters were stripped and reprobed when necessary, and lastly hybridized with a B-actin probe to control for loading. The probes used were TP53 (ATCC), WAF-1 (kind gift of B Vogelstein), and MDM2 (generated by PCR). For protein analysis, cell lysates were prepared, and 50 mg aliquots of clari®ed lysate protein were electrophoretically separated in 12% SDS-polyacrylamide gels, transferred to BA-S 83 membrane (Schliecher and Schuell), and immunoblotted as previously described by us (Houldsworth et al., 1997) . The primary antibodies used were p53 (DO-1, mouse IgG 2a antihuman monoclonal antibody), and bax (P-19, rabbit antihuman polyclonal antibody). For detection, horseradish peroxidase-conjugated goat antirabbit or antimouse antibodies were used, followed by enhanced chemiluminescence (ECL, Amersham Corp.). All antibodies were purchased from Santa Cruz Biotechnology with the exception of p53 that was purchased from Oncogene Science.
